New Analysis Demonstrates Reduced Risk of Cardiovascular Death or Worsening Heart Failure With Semaglutide

Learn more

About Saint Luke's Cardiovascular Research

Industry-Leading Clinical Research     
Clinical research is the foundation for improving patient care. Saint Luke’s uses leading-edge research to advance cardiovascular medicine, always with the goal of benefiting the patient, continuously striving to improve outcomes and patients' quality of life.

Advancing Cardiovascular Medicine     
At Saint Luke’s Mid America Heart Institute, our research programs span multiple key areas, including cardiac transplantation, electrophysiology, cardiac imaging, preventative cardiology, and cardiometabolic disease.

In addition to supporting clinical research, Saint Luke's has centers of cardiovascular excellence and core laboratories in cardiovascular outcomes and cardiometabolic research; health economics and technology assessment; intravascular imaging; and noninvasive imaging.

Our program is truly comprehensive, from preventive care to treating the most complex and serious conditions.

A Leader In Cardiovascular Research     
In recent years, Saint Luke’s researchers have annually published more than 300 peer-reviewed scientific articles in well-respected medical journals such as the New England Journal of Medicine, Journal of American Medical Association, The Lancet, Circulation, and the Journal of the American College of Cardiology.

The Heart Institute serves as one of four designated data analytic centers for the American College of Cardiology and the National Cardiovascular Data Registry, and is leading multiple global trials across different therapeutic areas.

Significant Accomplishments In Research

• Actively involved in more than 100 clinical trials
• Pioneers in Interventional Cardiology
  • First Balloon Angioplasty
  • First Transcatheter Aortic Valve Replacement (TAVR) in Midwest
  • Leaders in Complex Coronary interventions
• Developed the international standards for quantifying patient-centered outcomes
  • Development of the Kansas City Cardiomyopathy Questionnaire
  • Development of the Seattle Angina Questionnaire
  • Development of the Peripheral Artery Questionnaire
• International, practice-changing ISCHEMIA Trial
• Leaders in the field of Cardiometabolic Disease
  • Central in studying SGLT2 inhibitors—first entirely novel class of medication in the past two decades to be approved for the treatment of heart failure across the entire range of ejection fractions
  • Leading the Design and Execution of numerous clinical trials of SGLT2 inhibitors with impact for international guidelines and clinical practice: DEFINE HF, PRESERVED HF
  • EMBRACE-HF, DAPA-HF, DELIVER, EMPULSE
  • DARE-19
  • Cardiometabolic Center of Excellence, and Cardiometabolic Center Alliance
  • First-of-a-kind decentralized trial (CHIEF-HF)
• Educating the next generation of clinicians and investigators
  • Advanced fellowships in all domains of cardiology
  • NIH-funded T32 in Cardiovascular Quality and Outcomes Research
  • Ben McCallister, MD, Clinical Scholar Program

About Saint Luke's Mid America Heart Institute

Saint Luke’s Mid America Heart Institute offers some of the most comprehensive heart and vascular care in the nation. The experts at the Heart Institute use the latest technology, research, and innovations to treat the full range of cardiovascular services, from disease prevention to heart transplantation.

With more specialized physicians, more experience, and more innovative treatment options, the Heart Institute is the third hospital in the U.S. to achieve Comprehensive Cardiac Center certification from The Joint Commission. Saint Luke's is proud to help advance cardiovascular care in the nation.